Gilead COVID therapy Veklury approved for those with renal impairment
Bill Oxford         
The US FDA has approved Gilead Sciences' (NASDAQ:GILD) COVID-19 treatment Veklury (remdesivir) for use in patients with severe renal impairment.
The updated prescribing information eliminates the requirement for eGFR testing before or during treatment.

The approval was based on two studies in this specific population.

More on Gilead

Gilead: Assessing How Shares Will Trade Over Upcoming Months (Technical Analysis)
Gilead Sciences: An Evolving Biopharma Navigating Through Challenges And Opportunities